Related Experiment Video
Updated: Jan 6, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis
S Ehrlich1, J Eufinger2, N Tahiri2
1Department of Medicine III, University Hospital Munich - Campus Großhadern, Munich, Germany. sabine.ehrlich@med.uni-muenchen.de.
Purpose:
Recent advances in the treatment of acute myeloid leukemia (AML) and optimized supportive care have improved survival outcomes. However, infections during remission induction chemotherapy remain a leading cause of morbidity and mortality. While antifungal prophylaxis is standard, the role of routine antibacterial prophylaxis is increasingly debated due to adverse effects and resistance. This study aimed to characterize infectious complications in a real-world AML cohort receiving induction chemotherapy without routine antibacterial prophylaxis.
Methods:
We retrospectively analyzed 103 adults with newly diagnosed AML who underwent intensive induction therapy at LMU University Hospital between January 2019 and December 2022. All patients received antifungal prophylaxis whereas antibacterial fluoroquinolone (FQ) prophylaxis was not administered. We assessed febrile episodes, clinically and microbiologically documented infections, ICU/IMC admissions, and 30-/90-day mortality.
Results:
Febrile episodes occurred in almost all patients. Clinically documented infections accounted for 29.8% and microbiologically confirmed infections for 22.9% of febrile events. Bacteraemia was evenly distributed between Gram-positive and Gram-negative pathogens; multidrug resistance was rare. Proven or probable invasive fungal infections occurred in 6.8% of patients. In 47.2% of cases, the cause of fever remained unknown. Infection-related 30-day mortality was 4.9%. Factors associated with increased 30-day mortality included age ≥ 65 years, ECOG ≥ 2, secondary AML, and ICU/IMC admission for infection.
Conclusion:
Infections remain a major challenge during AML induction therapy. Our findings suggest that FQ prophylaxis should be reevaluated in this setting, focussing on a more individualized approach. In addition, novel diagnostic tools are urgently needed to enable earlier and more targeted infection management in this high-risk population.
Insights
Routine antibacterial prophylaxis may not be necessary for acute myeloid leukemia (AML) patients undergoing induction chemotherapy. This study found low rates of serious bacterial infections and resistance, suggesting a need for individualized prophylaxis strategies.
Area of Science:
- Hematology
- Infectious Diseases
- Oncology
Background:
- Infections are a major cause of morbidity and mortality in acute myeloid leukemia (AML) patients during induction chemotherapy.
- While antifungal prophylaxis is standard, the necessity of routine antibacterial prophylaxis is debated due to resistance and adverse effects.
Purpose of the Study:
- To evaluate infectious complications in AML patients receiving induction chemotherapy without routine antibacterial prophylaxis.
- To characterize the incidence of febrile episodes, documented infections, and mortality in this cohort.
Main Methods:
- Retrospective analysis of 103 adult AML patients treated between 2019-2022.
- Patients received antifungal but not fluoroquinolone (FQ) antibacterial prophylaxis.
- Outcomes assessed included febrile episodes, documented infections, ICU admissions, and 30-/90-day mortality.
Main Results:
- Nearly all patients experienced febrile episodes.
- Clinically and microbiologically documented infections occurred in 29.8% and 22.9% of febrile events, respectively.
- Bacteraemia was balanced between Gram-positive and Gram-negative pathogens with rare multidrug resistance; invasive fungal infections occurred in 6.8%.
Conclusions:
- Infections pose a significant challenge in AML induction therapy.
- Fluoroquinolone prophylaxis should be reconsidered, favoring an individualized approach.
- Novel diagnostic tools are crucial for timely and targeted infection management in high-risk AML patients.
Related Concept Videos
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:27Acute Pyelonephritis I: Introduction
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:26Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.